By Andrea Park
A proof-of-concept study found that Hagar’s radio frequency technology was able to continuously measure blood glucose levels with at least 90% accuracy, compared to the estimated 70% rate for traditional continuous glucose monitors.
read more
By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner
Eli Lilly will require all of its workers in the U.S. and Puerto Rico to get vaccinated against the virus by Nov. 15. The director of the CDC confirmed that the FDA is working with Moderna and Pfizer over booster shots for Americans with weak immune systems, although the elderly might not be included. Plus more headlines.
read more
By Heather Landi
The COVID-19 pandemic put a spotlight on existing healthcare disparities, but in communities throughout the U.S., public health leaders have been trying to tackle systemic inequities for years with limited success. Efforts have been siloed and technology has not been part of the conversation, industry leaders say.
read more
By Kevin Dunleavy
An FDA approval for COVID-19 booster shots for the immunocompromised appears imminent, according to NBC News, which could then touch off nods for the elderly and the general population.
read more
By Dave Muoio
Creaghan Harry was indicted in 2019 for his alleged role in one of the largest Medicare fraud and kickback schemes pursued by the Department of Justice. New superseding charges outline his alleged efforts to conceal the proceeds through shell companies and evade tax payments.
read more
By Conor Hale
Two companies working to reshape the field of ultrasound have joined forces, with Caption Health looking to bring its artificial intelligence-guided exams to Butterfly Network’s handheld diagnostic probes.
read more
By Robert King
Biden outlined a bold agenda to tackle drug prices, directing Congress to give Medicare wide authority to negotiate lower prices with drugmakers.
read more
By Noah Higgins-Dunn
Trying to fill a recent shortage for Pfizer’s smoking med Chantix, the FDA approved Par Pharmaceuticals’ copycat version “well ahead” of its expected review date, the agency said.
read more
.png)
